I reviewed Mary Otto’s excellent, heartrending new book for the New Republic.
My latest for the Guardian on the AHCA and the revised Congressional Budget Office score.
I was interviewed by Sarah Jaffe for her great “Interviews for Resistance” series on the ongoing healthcare fight, up today at In These Times.
I chatted with Matt Bubala at WGN Radio in Chicago about Trumpcare, Obamacare, and real universal healthcare, available here.
My latest for the Guardian US on the American Health Care Act. Who wins? Who loses? Where to next?
Yesterday, the Lancet published a new series “America: equity and equality in health.” It is available online for free (you need only to register on the site). In addition to the five papers (below), there is an accompanying editorial as well as comments from Senator Bernie Sanders and Thomas Sequist. I had the pleasure of co-writing the paper on the Affordable Care Act with colleague/mentor, Dr. Danny McCormack. The papers are:
- “Inequality and the health-care system in the USA”, Samuel L Dickman, David U Himmelstein, Steffie Woolhandler
- “Population health in an era of rising income inequality: USA, 1980–2015,” Jacob Bor, Gregory H Cohen, Sandro Galea
Joined Katie Halper and Gabe Pacheco to chat about myths around Medicare-for-all and much more.
On “Real News” again, discussing prospects for single-payer in light of Trumpcare’s collapse.
In a BMJ podcast online today, I debate Dr. Saurabh Jha on the future of US healthcare.
In this piece for the Guardian, I analyze the collapse of Trumpcare from the perspective of the right wing healthcare ethos (my Jacobin piece this morning looks at it from the perspective of the Left).
Some brief thoughts on Trumpcare and single payer etc etc in Jacobin today.
On the eve of the AHCA vote, me and Dr. Zackary Berger make the case against ACA repeal, in the British Medical Journal in a pro/con debate with Dr. Saurabh Jha.
An important study was published this week in the Annals of Internal Medicine, “Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States,” by Anne L. Stephenson and colleagues.1 The investigators used cystic fibrosis (CF) registries in the United States and Canada to compare outcomes for these patients between the two countries, and the bottom line made headlines in major media outlets: Canadian CF patients did better—much better—indeed they lived some 10 years longer than US CF patients. The investigators found 34% lower mortality for Canadian CF patients even after controlling for a wide variety of patient and clinical characteristics, including genotype, an important marker of disease severity. This difference was demonstrated in multiple subgroup analyses (for instance, when looking only at delta F508 homozygotes). Moreover, over time, Canadian CF patients saw greater improvements in life expectancy. Finally, they were also more likely to receive organ transplants.
Thus, despite the often-vaunted superiority of the American healthcare system, here is yet another piece of evidence that single payer public systems can deliver better results—indeed in this case the Canadian system even provided more high-technological care (i.e. transplants), which is supposed to be our specialty.
There is one additional finer point to make. When examining US CF patients by insurance status, the investigators found that those with private insurance did not do significantly worse than Canadian CF patients, whereas the uninsured and those with Medicare/Medicaid (treated as one category) did. Does this somehow provide evidence that private insurance is superior to public insurance, or does it weaken the overall point that the Canadian single payer system better served CF patients? No, for a number of reasons. First, Medicaid, as important as it is, does in fact sometimes provide a lower tier of access to medical care: for instance, CF patients with Medicaid are less likely to be accepted for a lung transplantation in the US.2 Thus, even apart from the possibility of residual confounding given the association of Medicaid with lower socioeconomic status, it would not be surprising to find worse outcomes for those with Medicaid as compared to those with private insurance in the US. Second, it is hard to use this study to say much about Medicare. In part, this is because subjects with Medicaid and Medicare were combined into a single group, so it’s unclear which (or both) of these populations were driving the finding. Additionally, those under 65 can only get Medicare if they are disabled. Comparing this disabled CF population to a general Canadian CF population would leave the door open for residual confounding.
- Stephenson AL, Sykes J, Stanojevic S, et al. Survival comparison of patients with cystic fibrosis in canada and the united states: A population-based cohort study. Annals of internal medicine 2017.
- Quon BS, Psoter K, Mayer-Hamblett N, Aitken ML, Li CI, Goss CH. Disparities in Access to Lung Transplantation for Patients with Cystic Fibrosis by Socioeconomic Status. American Journal of Respiratory and Critical Care Medicine 2012;186:1008-13.
I wrote about Paul Ryan, Trumpcare, and the meaning of healthcare “freedom” for the Guardian.
I have an article about the House GOP reform bill for Fortune up this morning.
I reviewed Peter Godfrey-Smith’s Other Minds: The Octopus, the Sea, and the Deep Origins of Consciousness for the New Republic.
Last November, I published a short post with rough estimates of the potential number of deaths per year that could result from a repeal of the ACA that was unaccompanied by a real replacement, and provided a rough range of 20,110 – 48,352 excess deaths (based on the “number needed to insure” from two studies as calculated by Sam Dickman et al. and the CBO’s estimate of 22 million more uninsured under Republican legislation).
Since then, we have some new estimates of the number of excess uninsured under repeal legislation. Bernie Sanders tweeted about the number of deaths that could result from ACA repeal, relying on other assumptions:
The Washington Post criticized the number, and assigned Bernie’s tweet four “pinocchios.” However, as Professors of Public Health David Himmelstein and Steffie Woolhandler (and PNHP co-founders) responded in an article also in the Post, Sanders number may actually be too low: they provided an estimate greater than 40,000 (based on 20 million uninsured). Here’s Atul Gawande responding to Himmelstein and Woolhandlers’ figure:
Of course, depending on the exact assumptions used, a range of numbers of estimated deaths can be calculated. The following table provides the potential range of estimated excess deaths per year depending on the assumption utilized.
|Number needed to insure|
|Source||Legislation||Number uninsured||“Low” estimate1||“Middle” estimate2||“High” estimate3|
|HHS4||Number insured by ACA||20,000,000||43,956||24,096||18,282|
|Congressional Budget Office5
|Restoring American’s Healthcare Freedom Reconciliation Act of 2015
|Urban Institute6||“repeal via reconciliation without replacement”||29,800,000||65,495||35,904||27,239|
Needless to say, all are rough approximations. What is important is that many body bags will be necessary if we gut the ACA, numbering in the tens of thousands. Many of these are approximations are even higher than that of Woolstein and Himmelhandler.
Of course, even with the ACA, we will have an estimated 26 million uninsured for 2017, according to the CBO, so the status quo is also very inadequate.
1 Sommers, B. D., S. K. Long, and K. Baicker. “Changes in Mortality after Massachusetts Health Care Reform: A Quasi-Experimental Study.” Annals of Internal Medicine 160, no. 9 (2014): 585-93. Number needed to insure based on this study as calculated by: Dickman, Sam, David Himmelstein, Danny McCormick, and Steffie Woolhandler. “Opting out of Medicaid expansion: the health and financial impacts.” Health Affairs Blog, January 30 (2014). Available at: http://healthaffairs.org/blog/2014/01/30/opting-out-of-medicaid-expansion-the-health-and-financial-impacts/.
2 Sommers, Benjamin D., Katherine Baicker, and Arnold M. Epstein. “Mortality and Access to Care among Adults after State Medicaid Expansions.” New England Journal of Medicine 367, no. 11 (2012): 1025-34.
3 Wilper, A. P., S. Woolhandler, K. E. Lasser, D. McCormick, D. H. Bor, and D. U. Himmelstein. “Health Insurance and Mortality in US Adults.” Am J Public Health 99, no. 12 (Dec 2009): 2289-95. Number needed to insure based on this study as calculated by: Dickman, Sam, David Himmelstein, Danny McCormick, and Steffie Woolhandler. “Opting out of Medicaid expansion: the health and financial impacts.” Health Affairs Blog, January 30 (2014). Available at: http://healthaffairs.org/blog/2014/01/30/opting-out-of-medicaid-expansion-the-health-and-financial-impacts/.
Updated to reflect “low estimate” of 455 number needed to insure, not 457.
Jacobin has an article today assessing the legacy of the Obama administration from a Left perspective; I wrote the portion about his healthcare legacy.
My thoughts on our likely next Secretary of Health and Human Services, Georgia Congressman and physician Tom Price, for In These Times.